Orca Biosciences
Seattle
Washington
United States
Tel: 206-336-5570
Website: http://www.orcabiosciences.com/
Email: orcabio@orcabiosciences.com
5 articles with Orca Biosciences
-
Nkarta announced that two of its therapies have shown complete remission in patients with blood cancer. These results are the latest development in the treatment of difficult-to-treat blood cancers.
-
Positive Clinical Results from More than 100 Patients Treated with Orca Bio’s Lead Investigational High Precision Cell Therapy Presented at 63rd ASH Annual Meeting
12/11/2021
Orca Bio, a clinical-stage biotechnology company developing purified, high-precision cell therapies for the treatment of cancer, autoimmune diseases and genetic blood disorders, announced positive clinical data on its lead investigational cell therapy, Orca-T, were presented at the American Society of Hematology Annual Meeting.
-
ASH 2020: CRISPR and Vertex's Potential Cure for Sickle Cell Disease and More Glimmers of Hope
12/7/2020
The American Society of Hematology (ASH) Annual Meeting & Exposition began December 5, and there were numerous presentations, abstracts and posters. Here’s a look at some of the stories out of the first day. -
First Clinical Data from Ongoing Orca-T Trial Shows Significantly Improved 12-Month Graft Versus Host Disease (GvHD)-Free and Relapse-Free Survival (GRFS) in Blood Cancer Patients Receiving a Hematopoietic Stem Cell Transplant (HSCT)
12/6/2020
Early multi-center results indicate that Orca-T, a novel approach to HSCT,improves time-to-engraftment, markedly reducesthe incidence and severity of GvHD, and significantly improved GRFS at 1 year
-
Orca Bio Emerges With Nearly $300 Million to Transform Allogeneic Cell Therapy
6/17/2020
Company aims to safely and effectively regenerate a healthy blood and immune system for patients with hematological malignancies, genetic diseases and autoimmune disorders